Drug Information Related to Peginterferon Alfa-2a
Back
01. EUROPEAN COMMISSION APPROVES SHORTENED HEPATITIS C TREATMENT. - Free ....
Roche has announced that the European Commission has approved a
shortened, 16-week course of treatment with Pegasys (peginterferon
alfa-2a (40 KD)) plus Copegus (ribavirin) for certain hepatitis C
patients.
The four-month treatment course will be for patients ...
02. The New England Journal of Medicine Publishes Research Examining ......
Business & Health Editors NUTLEY Nutley, town (1990 pop. 27,099), Essex co., NE N.J., a residential suburb of Newark, on the Passaic River; settled 1680, inc. 1902. Pharmaceuticals, dyestuffs, and machinery are made. After the Civil War the town was a cente...
03. Customizing Treatment with PEGASYS(R) May Improve Chances for Success ...
-- Results From Two Clinical Trials Point to Innovative Treatment Strategies -- BOSTON -- Patients with chronic hepatitis C who respond quickly to PEGASYS([R]) (peginterferon peginterferon /peg·in·ter·fer·on/ (peg?in?ter-fer´on) a covalent conjugate of rec...
04. Inhale's Technology Used in Recently-Approved Hepatitis C Treatment .....
Business Editors/High-Tech WritersFDA Approves Pegasys(R) (peginterferon alfa-2a) in combination withCopegus(TM) (ribavirin) for the treatment of Hepatitis CSAN CARLOS, Calif.--(BUSINESS WIRE)--Dec. 16, 2002Inhale Therapeutic Systems, Inc. (Nasdaq:INHL) today reported...
05. Enzon Announces Schering-Plough In-Licensing Agreement With Roche ......
Business & Health Editors PISCATAWAY, N.J--(BUSINESS WIRE)--Aug. 13, 2001 Enzon, Inc. (NASDAQ:ENZN) announced today that Schering-Plough (NYSE:SGP) has reported that it has entered into a licensing agreement with F.Hoffmann-La Roche Ltd and Hoffmann-La Roche In...
06. Health Canada, Novartis warn of risks to patients taking Sebivo and .....
Novartis Pharmaceuticals Canada and Health Canada notified health
care professionals March 7 of an increased risk of peripheral neuropathy
observed in chronic hepatitis B patients treated with Sebivo
(telbivudine) in combination with Pegasys (peginterferon alfa-2...
07. Vertex Announces Publication of Abstracts for Presentation at 58th ......
-- Conference Presentations to Include Data from Two Randomized,
Controlled Phase 2 Clinical Studies of Investigational HCV Protease
Inhibitor Telaprevir --
CAMBRIDGE, Mass. -- Vertex Pharmaceuticals Incorporated (Nasdaq:
VRTX) today announced that 6 abstracts...
08. SciClone begins phase 3 Zadaxin triple therapy hepatitis C trial in .....
SciClone Pharmaceuticals, Inc., San Mateo, CA, announced it has
begun a multi-center phase 3 hepatitis C triple therapy clinical trial
in Europe. The company says its European marketing and development
partner, Sigma-Tau, will conduct the Phase 3 multicenter, do...
09. Hepatitis coinfection: two major studies published. - Free Online Libr...
Two large clinical trials on treating hepatitis C in patients also infected with HIV (1,2) were published July 29, 2004, in the New England Journal of Medicine. The results were already known because they had been presented at the 2004 Retroviruses conference (abstra...
10. PEGASYS(R) Study Authors Conclude that Patients Successfully Treated ....
WASHINGTON -- Results from a new study, presented at the 38th
annual Digestive Disease Week (DDW) conference, showed that more than 99
percent of patients with chronic hepatitis C virus (HCV) infection who
were treated successfully with PEGASYS([R]) (peginterfero...
11. Schering-Plough to Initiate First Head-to-Head Study of Leading ......
Schering-Plough Corporation (NYSE: SGP)
today
announced plans to initiate a major clinical study involving 2,880 patients
that for the first time will directly compare the two approved forms of
pegylated interferon therapy(1) for chronic hepatitis C virus (HCV)
infect...
12. Hepatitis C: FDA public meeting on peginterferon plus ribavirin, Nov ....
On November 14 the Antiviral Drugs Advisory Committee will review the application by Hoffmann-La Roche for approval of peginterferon alfa-2a combined with ribavirin. The meeting will include time for public comment, and comments can also be submitted in writing. If yo...
13. Hepatitis coinfection: two major studies published | AIDS Treatment .....
Two large clinical trials on treating hepatitis C in patients also infected with HIV (1,2) were published July 29, 2004, in the New England Journal of Medicine. The results were already known because they had been presented at the 2004 Retroviruses conference (abstrac...
14. European Commission Approves Shortened Hepatitis C Treatment ...
Roche has announced that the European Commission has approved a shortened, 16-week course of treatment with Pegasys (peginterferon alfa-2a (40 KD)) plus Copegus (ribavirin) for certain hepatitis C patients.
...
15. Schering-Plough Announces FDA Approval of PEG-INTRON REDIPEN(TM) for ....
Schering-Plough Corporation (NYSE: SGP)
today announced that the U.S. Food and Drug Administration (FDA) has
granted marketing approval to PEG-INTRON REDIPEN™, a pre-filled pen for
administering PEG-INTRON® (peginterferon alfa-2b) Powder for Injection,
the m...
16. Weekly Interferon Effective in Treatment of Hepatitis C | American ......
The most effective therapy to date in the treatment of chronic hepatitis C virus (HCV) infection in patients with cirrhosis has been injectable interferon, usually in combination with oral ribavirin. Unfortunately, interferon has significant side effects, and the curr...
17. Inhale's Technology Used in Recently-Approved Hepatitis C Treatment .....
Business Editors/High-Tech Writers
...
